HC Wainwright Lowers Earnings Estimates for Jade Biosciences

Key Points

• HC Wainwright cut near-term EPS estimates for Jade Biosciences (example: Q1 2026 from ($0.41) to ($0.50); FY2026 to ($2.02) and FY2027 to ($2.09)) but kept a "Buy" rating and raised its price target to $35.
• Market consensus remains a Moderate Buy with an average target of $29.50, and Jade recently beat the quarter with ($0.11) EPS vs. consensus ($0.45), suggesting mixed near-term metrics amid longer‑term optimism.
• Shares trade around $13.95 with a market cap of $688M and a wide 52‑week range ($6.57–$100.10), while several institutional investors (e.g., Invesco, Opaleye) have notably increased or initiated positions.

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Research analysts at HC Wainwright cut their Q1 2026 EPS estimates for Jade Biosciences in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.50) per share for the quarter, down from their prior forecast of ($0.41). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. HC Wainwright also issued estimates for Jade Biosciences' Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.52) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.09) EPS.

A number of other equities research analysts also recently commented on JBIO. Lifesci Capital raised Jade Biosciences to a "strong-buy" rating in a research report on Friday, March 6th. Stifel Nicolaus set a $40.00 target price on Jade Biosciences in a research report on Friday, March 6th. William Blair raised Jade Biosciences to a "strong-buy" rating in a research note on Monday, March 9th. Wedbush restated an "outperform" rating and issued a $24.00 price target on shares of Jade Biosciences in a report on Monday, March 9th. Finally, BTIG Research increased their price objective on shares of Jade Biosciences from $28.00 to $39.00 and gave the stock a "buy" rating in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Jade Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Jade Biosciences Price Performance

Shares of Jade Biosciences stock opened at $13.95 on Friday. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $100.10. The firm has a market cap of $688.01 million, a PE ratio of -3.03 and a beta of 1.03. The business's fifty day moving average is $14.70 and its two-hundred day moving average is $12.50.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last announced its earnings results on Friday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.34.

Institutional Investors Weigh In On Jade Biosciences

Large investors have recently made changes to their positions in the business. Invesco Ltd. raised its stake in shares of Jade Biosciences by 477.6% in the 4th quarter. Invesco Ltd. now owns 199,727 shares of the company's stock valued at $3,082,000 after acquiring an additional 165,151 shares during the period. Ikarian Capital LLC purchased a new stake in Jade Biosciences during the 4th quarter worth $4,629,000. Virtus Investment Advisers LLC acquired a new stake in Jade Biosciences in the 4th quarter valued at $274,000. Opaleye Management Inc. acquired a new stake in Jade Biosciences in the 4th quarter valued at $6,598,000. Finally, Millennium Management LLC purchased a new position in Jade Biosciences in the fourth quarter valued at about $969,000.

Key Jade Biosciences News

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright raised its price target to $35.00 (from $25) and maintained a "Buy" rating, implying substantial upside from current levels — a clear positive catalyst that can drive buying interest. Article Title
• Neutral Sentiment: The firm continues coverage with a bullish view on longer-term value (FY2027 PT $35) even as it updates near-term metrics; that keeps institutional support but may moderate conviction until clinical/operational milestones justify the valuation.
• Negative Sentiment: HC Wainwright lowered multiple near-term EPS estimates: Q1–Q4 2026 and several 2027 quarters were reduced (examples: Q1 2026 from ($0.41) to ($0.50); FY2026 from ($1.74) to ($2.02); FY2027 from ($2.05) to ($2.09)). Those cuts signal a longer path to profitability and create downward pressure on the stock despite the higher target.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.